These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 12892834)

  • 1. Inhibition of arterial thrombosis by a protease-activated receptor 1 antagonist, FR171113, in the guinea pig.
    Kato Y; Kita Y; Hirasawa-Taniyama Y; Nishio M; Mihara K; Ito K; Yamanaka T; Seki J; Miyata S; Mutoh S
    Eur J Pharmacol; 2003 Jul; 473(2-3):163-9. PubMed ID: 12892834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro antiplatelet profile of FR171113, a novel non-peptide thrombin receptor antagonist.
    Kato Y; Kita Y; Nishio M; Hirasawa Y; Ito K; Yamanaka T; Motoyama Y; Seki J
    Eur J Pharmacol; 1999 Nov; 384(2-3):197-202. PubMed ID: 10611442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiplatelet and antithrombotic effect of F 16618, a new thrombin proteinase-activated receptor-1 (PAR1) antagonist.
    Dumas M; Nadal-Wollbold F; Gaussem P; Perez M; Mirault T; Létienne R; Bourbon T; Grelac F; Le Grand B; Bachelot-Loza C
    Br J Pharmacol; 2012 Mar; 165(6):1827-1835. PubMed ID: 21913899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of two synthetic glycoprotein IIb/IIIa antagonists, Ro 43-8857 and L-700,462, on platelet aggregation and bleeding in guinea-pigs and dogs: evidence that Ro 43-8857 is orally active.
    Cook NS; Bruttger O; Pally C; Hagenbach A
    Thromb Haemost; 1993 Nov; 70(5):838-47. PubMed ID: 8128443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The novel and orally active thrombin receptor antagonist E5555 (Atopaxar) inhibits arterial thrombosis without affecting bleeding time in guinea pigs.
    Kogushi M; Matsuoka T; Kawata T; Kuramochi H; Kawaguchi S; Murakami K; Hiyoshi H; Suzuki S; Kawahara T; Kajiwara A; Hishinuma I
    Eur J Pharmacol; 2011 Apr; 657(1-3):131-7. PubMed ID: 21300059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A highly constrained cyclic (S,S)-CDC- peptide is a potent inhibitor of carotid artery thrombosis in rabbits.
    Roussa VD; Stathopoulou EM; Papamichael ND; Englezopoulos CV; Rousouli KI; Trypou P; Moussis V; Tellis CC; Katsouras CS; Tsikaris V; Tselepis AD; Michalis LK
    Platelets; 2011; 22(5):361-70. PubMed ID: 21158497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protease-activated receptor 1 antagonists prevent platelet aggregation and adhesion without affecting thrombin time.
    Nadal-Wollbold F; Bocquet A; Bourbon T; Létienne R; Le Grand B
    Eur J Pharmacol; 2010 Oct; 644(1-3):188-94. PubMed ID: 20655904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the antithrombotic effects of FK633, GPIIb/IIIa antagonist, and aspirin in a guinea pig thrombosis model.
    Aoki T; Cox D; Senzaki K; Seki J; Tanaka A; Takasugi H; Motoyama Y
    Thromb Res; 1998 Feb; 89(3):129-36. PubMed ID: 9622041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antithrombotic effects of TAK-029, a novel GPIIb/IIIa antagonist, in guinea pigs: comparative studies with ticlopidine, clopidogrel, aspirin, prostaglandin E1 and argatroban.
    Kawamura M; Imura Y; Moriya N; Kita S; Fukushi H; Sugihara H; Nishikawa K; Terashita Z
    J Pharmacol Exp Ther; 1996 Apr; 277(1):502-10. PubMed ID: 8613960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blocking the protease-activated receptor 1-4 heterodimer in platelet-mediated thrombosis.
    Leger AJ; Jacques SL; Badar J; Kaneider NC; Derian CK; Andrade-Gordon P; Covic L; Kuliopulos A
    Circulation; 2006 Mar; 113(9):1244-54. PubMed ID: 16505172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of a synthetic peptide corresponding to residues 313 to 320 of the alphaIIb subunit of the human platelet integrin alphaIIbbeta3 on carotid artery thrombosis in rabbits.
    Papamichael ND; Stathopoulou EM; Roussa VD; Tsironis LD; Kotsia AP; Stanica RM; Moussis V; Tsikaris V; Katsouras CS; Tselepis AD; Michalis LK
    J Pharmacol Exp Ther; 2009 May; 329(2):634-40. PubMed ID: 19244095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antithrombotic effects of PAR1 and PAR4 antagonists evaluated under flow and static conditions.
    Hosokawa K; Ohnishi T; Miura N; Sameshima H; Koide T; Tanaka KA; Maruyama I
    Thromb Res; 2014 Jan; 133(1):66-72. PubMed ID: 24268424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparative study of the antithrombotic effect of aurintricarboxylic acid on arterial thrombosis in rats and guinea pigs.
    Takiguchi Y; Shimazawa M; Nakashima M
    Br J Pharmacol; 1996 Aug; 118(7):1633-8. PubMed ID: 8842425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anticoagulant and antithrombotic properties of intracellular protease-activated receptor antagonists.
    Wielders SJ; Bennaghmouch A; Reutelingsperger CP; Bevers EM; Lindhout T
    J Thromb Haemost; 2007 Mar; 5(3):571-6. PubMed ID: 17166251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blockade of protease-activated receptor-4 (PAR4) provides robust antithrombotic activity with low bleeding.
    Wong PC; Seiffert D; Bird JE; Watson CA; Bostwick JS; Giancarli M; Allegretto N; Hua J; Harden D; Guay J; Callejo M; Miller MM; Lawrence RM; Banville J; Guy J; Maxwell BD; Priestley ES; Marinier A; Wexler RR; Bouvier M; Gordon DA; Schumacher WA; Yang J
    Sci Transl Med; 2017 Jan; 9(371):. PubMed ID: 28053157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The preparation and characterization of novel peptide antagonists to thrombin and factor VIIa and activation of protease-activated receptor 1.
    Nieman MT; Warnock M; Hasan AA; Mahdi F; Lucchesi BR; Brown NJ; Murphey LJ; Schmaier AH
    J Pharmacol Exp Ther; 2004 Nov; 311(2):492-501. PubMed ID: 15210836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Administration of a potent antagonist of protease-activated receptor-1 (PAR-1) attenuates vascular restenosis following balloon angioplasty in rats.
    Andrade-Gordon P; Derian CK; Maryanoff BE; Zhang HC; Addo MF; Cheung Wm ; Damiano BP; D'Andrea MR; Darrow AL; de Garavilla L; Eckardt AJ; Giardino EC; Haertlein BJ; McComsey DF
    J Pharmacol Exp Ther; 2001 Jul; 298(1):34-42. PubMed ID: 11408522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiplatelet and antithrombotic activity of cilostazol is potentiated by dipyridamole in rabbits and dissociated from bleeding time prolongation.
    Li H; Cone J; Fong M; Kambayashi J; Yoshitake M; Liu Y
    Cardiovasc Drugs Ther; 2005 Jan; 19(1):41-8. PubMed ID: 15883755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. S-nitrosoderivative of a recombinant fragment of von Willebrand factor (S-nitroso-AR545C) inhibits thrombus formation in guinea pig carotid artery thrombosis model.
    Gurevitz O; Eldar M; Skutelsky E; Tamarin I; Shenkman B; Eskaraev R; Castel D; Loscalzo J; Inbal A
    Thromb Haemost; 2000 Nov; 84(5):912-7. PubMed ID: 11127876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of the therapeutic index of marketed anti-coagulants and anti-platelet agents by guinea pig models of thrombosis and hemostasis.
    Bird JE; Giancarli MR; Allegretto N; Barbera F; Wong P; Schumacher WA; Ogletree ML; Seiffert D
    Thromb Res; 2008; 123(1):146-58. PubMed ID: 18479740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.